Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 786

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies

Open access
Hormones, Endogenous·2008·JNCI: Journal of the National Cancer Institute
DOI 10.1093/jnci/djm323
Open this paper in CoChat — free account

Abstract

BACKGROUND: Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. We performed a collaborative analysis of the existing worldwide epidemiologic data to examine these associations in a uniform manner and to provide more precise estimates of risks. METHODS: Data on serum concentrations of sex hormones from 18 prospective studies that included 3886 men with incident prostate cancer and 6438 control subjects were pooled by the Endogenous Hormones and Prostate Cancer Collaborative Group. Relative risks (RRs) of prostate cancer by fifths of serum hormone concentration were estimated by use of conditional logistic regression with stratification by study, age at recruitment, and year of recruitment. All statistical tests were two-sided. RESULTS: No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol. The serum concentration of sex hormone-binding globulin was modestly inversely associated with prostate cancer risk (RR in the highest vs lowest fifth = 0.86, 95% confidence interval = 0.75 to 0.98; P(trend) = .01). There was no statistical evidence of heterogeneity among studies, and adjustment for potential confounders made little difference to the risk estimates. CONCLUSIONS: In this collaborative analysis of the worldwide data on endogenous hormones and prostate cancer risk, serum concentrations of sex hormones were not associated with the risk of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djm323

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Ferlay, 2004, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide
  2. Bostwick, 2004, Human prostate cancer risk factors, Cancer, 101, 2371, 10.1002/cncr.20408 · DOI · Paper page
  3. Hsing, 2001, Hormones and prostate cancer: what's next?, Epidemiol Rev, 23, 42, 10.1093/oxfordjournals.epirev.a000795 · DOI · Paper page
  4. Platz, 2004, The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer, J Steroid Biochem Mol Biol, 92, 237, 10.1016/j.jsbmb.2004.10.002 · DOI · Paper page
  5. Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 · DOI · Paper page
  6. Canby-Hagino, 2007, Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention, Eur Urol, 51, 27, 10.1016/j.eururo.2006.09.002 · doi:10.1016/j.eururo.2006.09.002
  7. Nomura, 1988, Prediagnostic serum hormones and the risk of prostate-cancer, Cancer Res, 48, 3515
  8. Barrett-Connor, 1990, A prospective, population-based study of androstenedione, estrogens, and prostatic-cancer, Cancer Res, 50, 169
  9. Hsing, 1993, Serological precursors of cancer—serum hormones and risk of subsequent prostate-cancer, Cancer Epidemiol Biomarkers Prev, 2, 27
  10. Comstock, 1993, The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate, Cancer Epidemiol Biomarkers Prev, 2, 219
  11. Carter, 1995, Longitudinal evaluation of serum androgen levels in men with and without prostate-cancer, Prostate, 27, 25, 10.1002/pros.2990270106 · DOI
  12. Corder, 1995, Seasonal-variation in vitamin-D, vitamin-D-binding protein, and dehydroepiandrosterone—risk of prostate-cancer in black and white men, Cancer Epidemiol Biomarkers Prev, 4, 655
  13. Gann, 1996, Prospective study of sex hormone levels and risk of prostate cancer, J Natl Cancer Inst, 88, 1118, 10.1093/jnci/88.16.1118 · DOI · Paper page
  14. Nomura, 1996, Serum androgens and prostate cancer, Cancer Epidemiol Biomarkers Prev, 5, 621
  15. Guess, 1997, 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera, Cancer Epidemiol Biomarkers Prev, 6, 21
  16. Vatten, 1997, Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway, Cancer Epidemiol Biomarkers Prev, 6, 967
  17. Dorgan, 1998, Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland, Cancer Epidemiol Biomarkers Prev, 7, 1069
  18. Heikkila, 1999, Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma—a longitudinal study, Cancer, 86, 312, 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.0.CO;2-7 · DOI
  19. Mohr, 2001, Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study, Urology, 57, 930, 10.1016/S0090-4295(00)01116-X · DOI
  20. Stattin, 2001, Plasma prolactin and prostate cancer risk: a prospective study, Int J Cancer, 92, 463, 10.1002/ijc.1191 · DOI
  21. Chen, 2003, Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial, Cancer Epidemiol Biomarkers Prev, 12, 1410
  22. Stattin, 2004, High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study, Int J Cancer, 108, 418, 10.1002/ijc.11572 · DOI
  23. Ozasa, 2004, Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men, Cancer Sci, 95, 65, 10.1111/j.1349-7006.2004.tb03172.x · DOI · Paper page
  24. Parsons, 2005, Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy, Cancer Epidemiol Biomarkers Prev, 14, 2257, 10.1158/1055-9965.EPI-04-0715 · DOI · Paper page
  25. Platz, 2005, Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era, Cancer Epidemiol Biomarkers Prev, 14, 1262, 10.1158/1055-9965.EPI-04-0371 · DOI · Paper page
  26. Severi, 2006, Circulating steroid hormones and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 86, 10.1158/1055-9965.EPI-05-0633 · DOI · Paper page
  27. Travis, 2007, Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 121, 1331, 10.1002/ijc.22814 · DOI
  28. Oliver, 2004, Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study, Int J Cancer, 108, 887, 10.1002/ijc.11631 · DOI
  29. Sodergard, 1982, Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature, J Steroid Biochem, 16, 801, 10.1016/0022-4731(82)90038-3 · DOI · Paper page
  30. Rinaldi, 2002, Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations, Cancer Epidemiol Biomarkers Prev, 11, 1065
  31. Kaaks, 2000, Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review, Prostate Cancer Prostatic Dis, 3, 157, 10.1038/sj.pcan.4500421 · DOI
  32. Eaton, 1999, Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies, Br J Cancer, 80, 930, 10.1038/sj.bjc.6690445 · DOI
  33. Shaneyfelt, 2000, Hormonal predictors of prostate cancer: a meta-analysis, J Clin Oncol, 18, 847, 10.1200/JCO.2000.18.4.847 · DOI · Paper page
  34. Bosland, 2000, Chapter 2: the role of steroid hormones in prostate carcinogenesis, J Natl Cancer Inst Monogr, 27, 39, 10.1093/oxfordjournals.jncimonographs.a024244 · DOI · Paper page
  35. Hsing, 1996, Hormones and prostate cancer: where do we go from here?, J Natl Cancer Inst, 88, 1093, 10.1093/jnci/88.16.1093 · DOI
  36. Russell, 1994, Steroid 5-α-reductase—2 genes 2 enzymes, Annu Rev Biochem, 63, 25, 10.1146/annurev.bi.63.070194.000325 · DOI · Paper page
  37. Norman, 1993, Androgen metabolism in men receiving finasteride before prostatectomy, J Urol, 150, 1736, 10.1016/S0022-5347(17)35882-2 · DOI
  38. Stanczyk, 1996, Alterations in circulating levels of androgens and PSA during treatment with finasteride in men at high risk of prostate cancer, 404, 10.1007/978-1-4612-2332-0_54 · doi:10.1007/978-1-4612-2332-0_54
  39. Rittmaster, 1988, Androstanediol glucuronide isomers in normal men and women and in men infused with labeled dihydrotestosterone, J Clin Endocrinol Metab, 66, 212, 10.1210/jcem-66-1-212 · DOI
  40. Thompson, 1990, Synthesis of new steroid haptens for radioimmunoassay—VIII. Development and validation of a specific radioimmunoassay for serum 5 alpha-androstane-3 alpha, 17 beta-diol 17-glucuronide, J Steroid Biochem, 36, 345, 10.1016/0022-4731(90)90227-J · doi:10.1016/0022-4731(90)90227-j
  41. Rao, 1987, Isolation and identification of androstanediol glucuronide from human plasma, J Steroid Biochem, 28, 565, 10.1016/0022-4731(87)90516-4 · DOI
  42. Tiitinen, 1994, Estrogen replacement does not potentiate gonadotropin-releaseing hormone agonist-induced androgen suppression in treatment of hirsutism, J Clin Endocrinol Metab, 79, 447
  43. Hankey, 1999, Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates, J Natl Cancer Inst, 91, 1017, 10.1093/jnci/91.12.1017 · DOI · Paper page
  44. Platz, 2004, Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era, J Cell Biochem, 91, 553, 10.1002/jcb.10700 · DOI
  45. Draisma, 2003, Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, 868
  46. Stenman, 1994, Serum concentrations of prostate specific antigen and its complex with [α]1-antichymotrypsin before diagnosis of prostate cancer, Lancet, 344, 1594, 10.1016/S0140-6736(94)90405-7 · doi:10.1016/s0140-6736(94)90405-7
  47. Breslow, 1977, Latent carcinoma of prostate at autopsy in 7 areas—collaborative study organized by International Agency For Research On Cancer, Lyons, France, Int J Cancer, 20, 680, 10.1002/ijc.2910200506 · DOI · Paper page
  48. McShane, 2001, Covariate measurement error adjustment for matched case-control studies, Biometrics, 57, 62, 10.1111/j.0006-341X.2001.00062.x · doi:10.1111/j.0006-341x.2001.00062.x
  49. Vermeulen, 1992, Representativeness of a single point plasma testosterone level for the long-term hormonal milieu in men, J Clin Endocrinol Metab, 74, 939, 10.1210/jcem.74.4.1548361 · doi:10.1210/jcem.74.4.1548361 · Paper page
  50. Ross, 1986, Serum testosterone levels in healthy-young black-and-white men, J Natl Cancer Inst, 76, 45
  51. Henderson, 1988, The early in utero estrogen and testosterone environment of blacks and whites—potential effects on male offspring, Br J Cancer, 57, 216, 10.1038/bjc.1988.46 · DOI · Paper page

Cited by

See all 786

Metadata

Authors
Hormones, E.
Venue
JNCI: Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2008-02-06
Volume
100
Issue
3
Pages
170-183
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
DOI
10.1093/jnci/djm323
OpenAlex
W2095618848
Cited by
786
References
2
FWCI
53.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. https://app.cochat.ai/papers/10.1093/jnci/djm323
The paper
Hormones, E. (2008). Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djm323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.